As per the agreement, both the companies will develop multi-specific products with extended half-lives, by exploiting the features of Nanobody.
Ablynx will receive an upfront payment of EUR20m and will take up the charge for all activities and costs for each programme, excluding manufacturing costs and costs relating to certain in vivo models.
In addition, Ablynx is also entitled to receive a further EUR15m for each programme if the pre- clinical packages are accepted by Merck Serono.